FDA Approved New Kidney Cancer Treatment Combination
The agency cleared a drug regimen for advanced renal cell carcinoma patients.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Should the FDA approve new drug combinations based primarily on progression-free survival data?
The FDA approved the use of belzutifan in combination with lenvatinib for adults with advanced renal cell carcinoma with a clear cell component. This treatment is specifically indicated for patients who have already received previous therapy with a PD-1 or PD-L1 inhibitor.
Why it matters
The new drug combination demonstrated a statistically significant improvement in progression-free survival compared to the standard treatment, cabozantinib. This provides a new therapeutic option for patients with limited options after initial immunotherapy.
In the LITESPARK-011 trial of 747 patients, the combination therapy achieved an objective response rate of 53 percent compared to 40 percent in the cabozantinib arm. Patients are advised to follow a daily dosage of 20 mg of lenvatinib and 120 mg of belzutifan.
The players
Food and Drug Administration
The federal agency is responsible for protecting public health by regulating the safety and efficacy of medical products in the United States.
The details
Researchers randomized patients in a 1:1 ratio to receive either the combination therapy or cabozantinib, with efficacy measured by independent review using RECIST v1.1 criteria. Prescribing information for belzutifan contains a boxed warning noting the risk of embryo-fetal toxicity.
Timeline
The FDA approved the combination therapy on September 24, 2026.
The Big Picture
This approval follows the evidence established by the LITESPARK-011 clinical trial, which has served as the foundational benchmark for assessing new combination therapies in advanced renal cell carcinoma treatment.
Patients may now discuss this new combination therapy with their oncologists to determine if it is a suitable treatment path following prior PD-1 or PD-L1 inhibitor failure. It is critical for patients to note the boxed warning regarding embryo-fetal toxicity before starting the regimen.
The takeaway
This new regimen offers a measurable improvement in progression-free survival for specific advanced kidney cancer patients. Patients and caregivers should prioritize discussions with medical professionals regarding the potential side effects and the specific daily dosage requirements.
Further reading
For more information on current treatment options, visit the Cancer section.
Live Poll
Should the FDA approve new drug combinations based primarily on progression-free survival data?
